12: Kamada CEO Amir London Discusses the Company's Work on AATD Therapies

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.